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Abstract
Background: Molecular assessment and treatment of metastatic colorectal cancer (mCRC) quickly evolved during
the last decades, hampering longitudinal evaluation of prognostic markers. The aim of this study was to evaluate
prognostic predictors of long-term survival in a retrospective series of mCRC, treated prior to the expanded RAS
assessment era.
Methods: mCRC cases treated at the Città della Salute e della Scienza University Hospital (Turin, Italy) between
January 2004 and December 2012 were evaluated, including cases with ≥ 5-year follow-up only. Long-term survival
was defined as an overall survival (OS) ≥ 4 years based on the observed OS interquartile range values. Univariate/
multivariate Cox proportional hazards regression models were performed to assess the prognostic significance of
the clinical/biological features, while binary logistic regression models were used to verify their associations with
long-term survival.
Results: Two hundred and forty-eight mCRC cases were included and analyzed. Sixty out of two hundred and
forty-eight (24%) patients were long-term survivors. Univariate binary logistic regression analysis demonstrated a
significant association between long-term survival and age at diagnosis < 65 (OR = 2.28, p = 0.007), single metastatic
site (OR = 1.89, p = 0.039), surgical resection of metastases (OR = 5.30, p < 0.001), local non-surgical treatment of
metastases (OR = 4.74, p < 0.001), and a bevacizumab-including first-line treatment schedule (OR = 2.19, p = 0.024).
Multivariate binary logistic regression analysis confirmed the prognostic significance of surgical resection of metastases
(OR = 3.96, p < 0.001), local non-surgical treatment of metastases (OR = 3.32, p = 0.001), and of bevacizumab-including
first-line treatment schedule (OR = 2.49, p = 0.024).
Conclusion: Long-term survival could be achieved in a significant rate of patients with mCRC even in an era of limited
molecular characterization. Local treatment of metastases proved to be a significant predictor of long-term survival.
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Background
Colorectal cancer (CRC) is a worldwide leading cause of
cancer and cancer-related deaths [1]. Over the past dec-
ade, CRC incidence and mortality decreased due to
multiple factors: screening protocols implementation, im-
proved surgical techniques, and availability of novel sys-
temic therapeutic options [2]. Nevertheless, metastatic
disease is already present at presentation in about 20% of
patients (stage IV), while about 30–40% of patients who
receive surgical resection will ultimately experience dis-
ease recurrence requiring systemic treatments [3].
Although initial disease stage remains the main out-
come predictor in CRC, in the precision medicine era,
tumor molecular profiling has become of paramount im-
portance [4]. The clinical and histopathological hetero-
geneity of CRC has been further supported by molecular
profiling and specific mutational profiles resulted to be
strongly correlated with clinical outcome and response
to treatment [5]. Therefore, assessment of specific tumor
characteristics and biomarkers [e.g., tumor site (right
versus left colon), mismatch repair capability, KRAS,
NRAS, and BRAF proto-oncogenes mutational statuses]
is now deemed mandatory for treatment selection in pa-
tients with mCRC, and the main therapeutic options in
this setting include chemotherapy drugs, targeted ther-
apies against the EGFR (Epidermal Growth Factor Re-
ceptor), and VEGF (Vascular Endothelial Growth Factor)
pathways and immunotherapy [6].
KRAS status was the first molecular predictive marker
to be routinely assessed in mCRC since several studies
proved that KRAS-mutant tumors do not benefit from
treatment with EGFR inhibitors. Initially, the effect was
thought to be restricted to patients with KRAS (exon 2)
wild-type tumors, but extended RAS analyses demon-
strated a lack of response also in patients with tumors
harboring other KRAS (exons 3 and 4) or NRAS muta-
tions [7–9]. Expanded RAS testing increased the RAS
mutation rate from 40% to about 55% [10], thus avoiding
a potentially ineffective or even harmful anti-EGFR ther-
apy in a significant number of patients. At the same
time, extended molecular testing identified the signifi-
cance of other markers, such as the adverse prognostic
effect of BRAF mutations at codon 600 [11].
In RAS-mutant metastatic CRC (mCRC) patients, first-
line therapies usually consist of combined approaches like
FOLFOX/CAPOX (5-fluorouracil plus oxaliplatin/capecit-
abine plus oxaliplatin) or FOLFIRI/CAPIRI (5-fluorouracil
plus irinotecan/capecitabine plus irinotecan) plus an add-
itional anti-angiogenetic biologic drug (bevacizumab,
ramucirumab, ziv-aflibercept) [12, 13]. In BRAF-mutated
tumors, a triple chemotherapeutic regimen is usually
taken into consideration (FOLFOXIRI: 5-fluorouracil plus
oxaliplatin and irinotecan). Conversely, in RAS wild-type
mCRC, EGFR inhibitors, like cetuximab or panitumumab,
are added to conventional chemotherapy drugs [7].
Tumor side also affects the choice of treatment, since left-
sided neoplasms shown higher response rates to anti-
EGFR treatments [14]. Most recently, novel options be-
came available: regorafenib, a multi-kinase inhibitor,
showed efficacy in previously treated mCRC [15–17],
whereas programmed cell death protein 1 (PD-1) targeting
by immunotherapy (e.g., nivolumab and pembrolizumab)
proved to be effective in mCRC with high microsatellite
instability (MSI-high) [18, 19].
Despite these efforts, the 5-year survival rate of mCRC
remains largely unsatisfying, ranging around just 15% of
patients [20]. An improved characterization of long-term
survivors is thus warranted to optimize these pa-
tients' care, but the quickly evolving landscape hampers
comparisons across long time periods.
The aim of this study was therefore to evaluate the
long-term survivors’ characteristics in a retrospective
series of mCRC treated prior to the expanded RAS as-
sessment era and with extended follow up available, to
define prognostic markers affecting progression free sur-
vival (PFS) and overall survival (OS).
Methods
Case series
This is a retrospective observational study on the mCRC
cases treated at the Colorectal Cancer Unit of the Città
della Salute e della Scienza University Hospital (Turin,
Italy) between January 2004 and December 2012. Our
study cohort included 248 mCRC (either at the initial
diagnosis of CRC or diagnosed with metastatic disease
during follow up) patients (≥ 18 year old) who underwent
at least one cycle of systemic anti-neoplastic treatment
(cytotoxic drug therapy with or without molecular tar-
geted agents). Cases with a follow-up time < 5 years were
excluded [median follow up was 7.58 years, IQR (inter-
quartile range) 5.41–9.16 years]. Considered the “real-life”,
observational nature of the study no other exclusion cri-
teria were established. The start of the study period was
chosen to collect a broadly homogenous cohort, account-
ing for the introduction of anti-angiogenetic and anti-
EGFR agents. Conversely, the accrual was stopped in 2012
prior to the deployment of expanded RAS assessment pro-
tocols and to achieve a sufficient follow-up. To define
long-term survivors (LTS), a survival time ≥ 4 years was
selected based upon the observed overall survival IQR
values (1.54–4.00 years): this cutoff value enabled to have
a representative number of cases (about one quarter of the
whole series) available for the subsequent analyses while
also being a clinically meaningful time period.
Clinical information was gathered from patients’
charts, hospital discharge forms, imaging repositories,
and contacts with general practitioners. Collected data
included gender, age at diagnosis, tumor side, KRAS
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status (exon 2, codons 12, and 13), number and sites of
metastases, details regarding systemic and locoregional
(surgery and/or radiofrequency) treatments, and disease
outcome (PFS and OS). Chemotherapy schedules com-
prised a combination of drugs including fluorouracil,
capecitabine, oxaliplatin, irinotecan, mitomycin, bevaci-
zumab, cetuximab, and panitumumab according to the
disease setting and available clinical trials.
The study was conducted in accordance with The
Code of Ethics of the World Medical Association (Dec-
laration of Helsinki) for experiments involving humans
and within the guidelines and regulations defined by the
Research Ethics Committee of the University of Turin.
This study was approved by the Research Ethics Com-
mittee of the University of Turin; considered the retro-
spective nature of the research protocol and that it had
no impact at all on patients’ care, no specific written in-
formed consent was required.
Statistical analyses
All analyses were performed using the Stata/MP 15.0 Stat-
istical Software (StataCorp, College Station, TX, USA).
Continuous variables were summarized by mean and
standard deviation (SD); whereas for categorical variables,
the frequency and percentage were provided. The charac-
teristics at diagnosis were compared using the chi-square
test for categorical variables and the T test or ANOVA
test for continuous ones.
The follow-up time, calculated with the reverse Kaplan–
Meier method, was summarized as median and interquartile
range (IQR). The survival times were measured from the start
of treatment at metastasis diagnosis until disease progression
(PFS) and death from any cause (OS); patients lost at follow-
up (after a minimum of 5 years as per inclusion criteria) were
censored on the last follow-up date. Survival curves were esti-
mated with the Kaplan–Meier method and compared by log-
rank test. The impact of possible confounders was explored
by univariate and multivariate Cox proportional hazards re-
gression models, including clinical/biological features as co-
variates. The proportional hazards assumption was tested for
all the endpoints. Hazard ratios (HR) and 95% confidence in-
tervals (95% CI) were estimated. Univariate/multivariate bin-
ary logistic regression models were performed using long-
term survival as the dependent variable (yes or no) and
patient/tumor characteristics as covariates. Odds ratios and
95% CIs were estimated. The Hosmer–Lemeshow goodness-
of-fit test was used to determine whether the model
adequately described the data. Differences were considered
significant when p < 0.05 for reported two-sided p values.
Results
Patients’ clinical and pathological characteristics
The clinical and pathological characteristics of patients
are presented in Table 1. The median age was 65 years
(range 32–82), and the male to female ratio was 1.32.
Primary tumor was right-sided in 83/248 (33%) cases,
left-sided in 97/248 (39%), and localized in the rectum
in 68/248 (28%). A KRAS mutation was detected in
45.2% of patients (based on codon 2 assessment only,
i.e., before expanded RAS protocols).
The overall number of treatment lines are reported in
Table 2. A higher rate of patients with an OS < 4 years
received only one line of treatment (18% versus 8%);
conversely, more long-term survivors (≥ 4 years) received
4 lines (47% versus 27%).
Overall outcome analysis
Median overall PFS after first-line treatment was 11.6
months (IQR 7.5–16.7 months), while median OS time
was 2.62 years (IQR 1.54–4.00 years), and 60 out of 248
(24%) patients were long-term survivors (OS ≥ 4 years)
(Fig. 1a).
At univariate analysis (Table 3), the variables signifi-
cantly associated with first-line PFS were age at diagnosis,
age at metastasis, surgical resection of primary tumor, sur-
gical resection of metastasis, local non-surgical treatment
of metastasis, and bevacizumab administration at first line.
Conversely, no correlation was found between gender,
tumor site (right sided versus other), site of metastases,
KRAS mutational status (based on exon 2 evaluation), or
adjuvant treatment.
Variables affecting OS were age at diagnosis, age at
metastasis, right-sided tumor, KRAS exon 2 mutational
status, surgical resection of primary tumor, surgical re-
section of metastasis, and local non-surgical treatment
of metastasis. No correlation was found with gender, site
of metastases, adjuvant treatment, or a bevacizumab-
including first-line regimen.
Multivariable Cox regression analysis was stratified by
local non-surgical treatment of metastases because this
covariate violated the proportional hazards assumption.
Surgical resection of metastasis was confirmed to be a
significant predictor in terms of first line PFS and/or OS
by multivariate analyses (Table 4), as well as first-line
treatment including bevacizumab, age at metastasis diag-
nosis, and right sided tumor.
Characteristics of long-term survivors
No significant differences were observed in terms of
gender, primary tumor site, histological grade, KRAS
mutational status, or adjuvant treatment according to
long-term survival status (Table 1). Conversely, long-
term survivors (≥ 4 years) showed a lower median age at
diagnosis (60 versus 66, p = 0.012) and at metastasis
diagnosis (62 versus 66 years, p = 0.026), a lower rate of
multiple metastatic sites (33.3 % versus 48.4%, p =
0.038), and higher rates of metastasis surgical treatment
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(63% versus 26%, p < 0.001) and/or local non-surgical
metastasis treatment (57% versus 21%, p < 0.001).
Long-term survivors also showed a significant longer
first-line treatment median PFS compared with other pa-
tients (15.7 versus 10.8months, respectively, p = 0.0001)
(Table 5 and Fig. 1b). This statistical difference was main-
tained in subsequent treatment lines as well (Table 5).
Outcome analysis of long-term survivors
Based on the previous results in terms of variables af-
fecting outcome, univariate binary logistic regression
analysis was performed (Table 6): a significant associ-
ation was observed between long-term survival and age
at diagnosis < 65, a single metastatic site, surgical resec-
tion of metastases, local non-surgical treatment of
Table 1 Clinico-pathological characteristics according to long-term survival status
Total
(n = 248)
Survivors < 4 years (n = 188) Long-term survivors
(≥ 4 years) (n = 60)
p value
Gender Female 102 79 23 0.613
Male 146 109 37
Age at diagnosis Median (range) (years) 65 (32–82) 66 (37–82) 60 (32-82) 0.012
Age at metastasis Median (range) (years) 65 (35–83) 66 (37–83) 62 (35–83) 0.026
Mutational status KRAS (exon 2) WT 136 100 36 0.651
Codon 12 mutation 88 69 19
Codon 13 mutation 24 19 5
Grading (not available 5; surgical resection
of primary tumor not performed 30)
1 7 5 2 0.646
2 140 102 38
3 66 52 14
pT
(not available 1; surgical resection of primary
tumor not performed 30)
1 3 1 2 0.052
2 11 7 4
3 136 97 39
4 72 55 12
Primary site Right side 83 69 14 0.150
Left side 97 71 26
Rectum 68 48 20
Primary site Right side 83 69 14 0.056
Left side + Rectum 165 119 46
Metastasis at diagnosis No 89 63 26 0.167
Yes 159 125 34
Metastatic site Liver 98 70 28 0.301
Lung 18 12 6
Peritoneum 15 11 4
Lymph nodes 5 3 2
Multiple sites 111 91 20
Number of metastatic sites Single site 136 96 40 0.038
Multiple sites 111 91 20
Surgical resection of primary tumor No 30 27 3 0.053
Yes 218 161 57
Adjuvant treatment No 169 132 37 0.216
Yes 79 56 23
Metastasis surgical resection No 159 140 22 <0.001
Yes 89 48 38
Local non-surgical treatment of metastasis No 174 148 26 <0.001
Yes 74 40 34
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metastases, and a bevacizumab-including first-line treat-
ment schedule.
Multivariate binary logistic regression analysis (Table 7)
confirmed the significant association between long-term
survival and surgical resection of metastases, local non-
surgical treatment of metastases, and a bevacizumab-
including first-line treatment schedule.
Based upon these results, we wanted to verify the asso-
ciation between these long-term survival (LTS) associ-
ated treatments and OS in the whole series. Considered
that both surgical and non-surgical local treatment of
metastases were aimed at the local control of a systemic
disease, we considered these two treatments as equiva-
lent. Thus, the identified LTS-associated treatments
were (i) bevacizumab at first line and (ii) surgical resec-
tion of metastasis and/or local non-surgical treatment of
metastasis. Kaplan–Meier analysis of the whole series (n
= 248) showed a significantly longer OS in patients
treated with LTS-associated treatments (log-rank test p
< 0.001): 3.92 years median (IQR 0.69–11.7) versus 2.15
years median (IQR 0.30–9.17) (Fig. 1c). Considering
local treatment of metastases exclusively (irrespectively
Table 2 Lines of treatment
Total (n = 248) Survivors < 4 years (n = 188) Long-term survivors (≥ 4 years) (n = 60)
Number of lines of treatment 1 39 (16%) 34 (18%) 5 (8%)
2 63 (25%) 51 (27%) 12 (20%)
3 67 (27%) 52 (28%) 15 (25%)
4 79 (32%) 51 (27%) 28 (47%)
Fig. 1 a Kaplan–Meier curve of OS. Median OS time was 2.62 years (red arrow), but survival was longer than 4 years in 24% of patients (green arrow).
b Kaplan–Meier curve of 1st-line treatment PFS according to LTS. c Kaplan–Meier curve of OS according to LTS-associated treatments (bevacizumab-
including 1st-line regimen, surgical resection of metastases, local non-surgical treatment of metastases). d Kaplan–Meier curve of OS according to local
treatment of metastases (either by surgery or other approaches)
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if by surgery or other approaches), an association with
longer OS was still confirmed (log-rank test < 0.001):
3.83 years median (IQR 2.23–5.26) versus 2.05 years me-
dian (IQR 1.37–3.26) (Fig. 1d).
Finally, considered the prognostic role of local metasta-
sis treatment, we verified the characteristics of metastatic
disease in the series (Table 8). Overall, a higher rate of sin-
gle metastases was found within long-term survivors com-
pared with other patients (67% versus 52%). Among
patients with single site metastases, a higher rate of long-
term survivors received local treatments (75% versus 22%
in patients with < 4 years survival).
Discussion
In the present study, outcome analysis of a real-life
series of mCRC treated prior to expanded KRAS assess-
ment and with long-term follow-up was performed: a
high rate (24%) of long-surviving patients (≥ 4 years) was
Table 3 PFS and OS univariate Cox regression analyses of the whole series
First-line PFS OS
Variable HR 95% CI p HR 95% CI p
Gender 1.00 0.77–1.29 0.991 1.11 0.84–1.46 0.438
Age at diagnosis 1.02 1.01–1.03 0.001 1.04 1.02–1.05 < 0.001
Age at metastasis 1.02 1.00–1.03 0.003 1.04 1.02–1.05 < 0.001
Age at metastasis > 60 years 1.40 1.07–1.65 0.015 1.76 1.30–2.38 < 0.001
Tumor grade 1 1 1
2 1.24 0.58–2.66 0.570 0.67 0.31–1.45 0.321
3 1.37 0.63–3.00 0.426 1.04 0.47–2.28 0.921
pT 1 1 1
2 0.82 0.18–3.74 0.806 1.27 0.27–6.00 0.764
3 1.04 0.25–4.21 0.956 1.92 0.47–7.81 0.360
4 1.31 0.32–5.36 0.706 2.76 0.67–11.39 0.158
Right sided tumor versus other (left sided and rectum) 1.24 0.94–1.61 0.115 1.36 1.03–1.80 0.030
Metastasis site Liver 1 1
Other sites 1.11 0.76–1.64 0.579 1.05 0.71–1.57 0.796
Multiple sites 1.29 0.97–1.70 0.070 1.17 0.88–1.57 0.277
Multiple site versus single site metastases 1.25 0.91.62 0.082 1.16 0.89–1.52 0.274
KRAS mutant (exon 2) versus wild-type 1.25 0.97–1.61 0.083 1.32 1.01–1.72 0.039
First-line therapy Chemotherapy plus bevacizumab 1 1
Chemotherapy plus anti-EGFR 1.03 0.49–2.13 0.933 1.05 0.45–2.41 0.909
Chemotherapy alone 1.44 1.09–1.88 0.008 0.91 0.68–1.22 0.544
First-line therapy Chemotherapy plus bevacizumab versus other 0.71 0.54–0.93 0.012 1.09 0.81–1.45 0.568
Surgical resection of primary tumor (yes versus no) 0.59 0.40-0.88 0.009 0.64 0.42–0.96 0.030
Surgical resection of metastasis (yes versus no) 0.55 0.41–0.72 < 0.001 0.44 0.32–0.59 < 0.001
Local non-surgical treatment of metastasis (yes versus no) 0.60 0.45–0.80 < 0.001 0.47 0.35–0.64 < 0.001
Table 4 PFS and OS multivariate Cox regression analyses of the whole series
First line PFS OS
Variable HR 95% CI 3.3. p HR 95% CI p
Gender 0.86 0.69–1.08 0.199 1.21 0.96–1.54 0.109
Age at metastasis 1.01 0.99–1.02 0.180 1.02 1.00–1.04 0.009
Chemotherapy plus bevacizumab versus other 0.70 0.66–0.74 < 0.001 – – –
Surgical resection of metastasis (Yes versus No) 0.57 0.44–0.71 < 0.001 0.49 0.39–0.61 < 0.001
Right-sided tumor versus other (left-sided and rectum) – – – 1.18 1.00–1.40 0.048
KRAS mutant (exon 2) versus wild-type – – – 1.28 0.75–2.18 0.365
Standard error adjusted for 2 clusters in local treatment
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observed, and their characteristics were evaluated. Local
treatment of metastases (surgical or non-surgical) and a
first-line treatment including bevacizumab resulted sig-
nificantly associated with PFS/OS and long-term survival
at univariate and multivariate analyses.
Overall characteristics of the series were as expected:
tumor involved right colon in 1/3 of cases, while the
neoplasm was left-sided (left colon or rectum) in the
remaining 2/3 [21]. Molecular status (KRAS mutation
rate of about 45%) was consistent with the results ob-
served prior to expanded KRAS evaluation [10]. Most of
the patients had synchronous metastases at diagnosis
(64%), and the majority of them had single site involve-
ment (55%).
mCRC is a leading cause of cancer-related death des-
pite our fast evolving knowledge regarding the molecular
inner-workings of this disease and the availability of
novel therapeutic options. Thanks to the introduction of
the FOLFOX/FOLFIRI schedules, median OS reached
the 2 years milestone, while addition of anti-angiogenetic
and anti-EGFR biological therapies led to a further im-
provement to about 30 months [22]. Despite the real-life
retrospective nature of our series and the time period
analyzed, we observed a median OS of more than 30
months which is in line or even superior to what could
have been expected, considered the analyzed years and
the now outdated molecular profiling based on KRAS
exon 2 evaluation only. This is a first interesting result
Table 5 PFS according to lines of treatment
Survivors < 4 years (n = 188) Long-term survivors (≥ 4 years) (n = 60) p value
n PFS (months) (IQR) n PFS (months) (IQR)
1st-line overall Median (interval) (months) 188 10.8 (0.7–46.6) 60 15.7 (3.5–69) 0.0001
Type of treatment Chemotherapy plus bevacizumab 71 12 (1–46.6) 13 25.9 (11.6–69)
Chemotherapy plus anti-EGFR 7 16.1 (6.5–32) 1 5.1
Chemotherapy alone 110 10.1 (0.7–39.1) 46 13.1 (3.5–60.8)
2nd-line overall Median (interval) (months) 154 4.4 (0.2–21.9) 51 9.8 (2.0–47.8) < 0.001
Type of treatment Chemotherapy plus bevacizumab 25 5.7 (1.3–19.4) 8 9.45 (2.1–24.3)
Chemotherapy plus anti-EGFR 28 3.05 (0.2–14.1) 5 10.3 (2.5–24.7)
Chemotherapy alone 101 4.3 (0.2–21.9) 38 9.65 (2–47.8)
3rd-line overall Median (interval) (months) 103 3.2 (0.6–20.2) 43 7.6 (0.2–33) < 0.001
Type of treatment Chemotherapy plus bevacizumab 1 4.65 (2.6–6.7) 3 8 (7.3–16.2)
Chemotherapy plus anti-EGFR 33 3.45 (0.6–9.9) 17 8.1 (1.9–33)
Chemotherapy alone 69 3.1 (0.4–20.2) 23 7.1 (0.2–28)
4th-line overall Median (interval) (months) 51 2.6 (0.6–8.8) 28 7.7 (2.2–17.9) < 0.001
Type of treatment Chemotherapy plus bevacizumab 0 – 1 12.1
Chemotherapy plus anti-EGFR 5 4.1 (2.6–8.8) 6 15.5 (8.2–17.9)
Chemotherapy alone 46 2.6 (0.6–7) 21 6.35 (2.2–17.1)
Table 6 Univariate binary logistic regression analysis of characteristics associated with long-term survival
Long-term survival
Variable OR 95% CI p
Gender 1.16 0.64–2.11 0.613
Age at metastasis ≤ 65 years (yes versus no) 2.28 1.25–4.15 0.007
Right-sided tumor versus other (left-sided and rectum) 0.52 0.26–1.02 0.058
Single site metastases versus multiple sites 1.89 1.03–3.48 0.039
KRAS mutant (exon 2) versus wild-type 0.74 0.41–1.33 0.321
First-line therapy Chemotherapy plus bevacizumab
versus other
2.19 1.11–4.33 0.024
Surgical resection of primary tumor (yes versus no) 3.18 0.93–10.9 0.065
Surgical resection of metastasis (yes versus no) 5.30 2.80–10 < 0.001
Local non-surgical treatment of metastasis (yes versus no) 4.74 0.11–0.27 < 0.001
Adjuvant treatment (yes versus no) 1.46 0.80–2.69 0.217
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and a possible explanation of this good overall outcome
could be the specific study setting: a tertiary university
hospital with a dedicated colorectal cancer unit. Man-
agement of patients with colorectal cancer by multidis-
ciplinary teams proved to be especially relevant for
advanced disease [23] and was found to be associated
with improved outcomes in multiple reports [24–28].
Lower age at metastasis (p = 0.009), surgical resection
of metastases (p < 0.001), and a left-sided tumor (p =
0.048) were associated with longer OS by multivariate
Cox regression analysis stratified by local treatment.
Data accrued during the last few years showed an associ-
ation between right sided primary tumors and poorer
outcome even when accounting for the specific tumor
molecular profile (like RAS status) or other variables [14,
29, 30]. This finding could be potentially due to the dif-
ferent embryologic origin of the right versus left colon
and is now being accounted for when designing new
clinical trials. Our results confirm these findings in a
large series with extended follow-up.
Focusing on long-term survivors (≥ 4 years), this group
differed in terms of (i) lower age at initial diagnosis (60
versus 66, p = 0.012) and at metastasis (62 versus 66
years, p = 0.026); (ii) lower rate of multiple metastatic
sites (33.3 % versus 48.4%, p = 0.038); (iii) higher rates of
surgical (63% versus 26%, p < 0.001) and/or local non-
surgical metastasis treatment (57% versus 21%, p < 0.001);
(iv) a significantly longer first-line treatment median PFS
(15.7 versus 10.8months respectively, p = 0.0001).
Although this latter association could be expected and
considered an example of responder bias, it is interesting
to note that the statistically significant difference was con-
firmed in all subsequent treatment lines as well; thus, the
sequential PFSs observed during the disease course seem
to remain informative to estimate patients’ outcome.
Regarding outcome analysis, the variables which showed
the strongest association with long-term survival were the
local treatments of metastases (either surgically or not).
This finding was confirmed by multivariate binary regres-
sion logistic analysis. The availability of a specific dedi-
cated multidisciplinary colorectal team probably had a
role in enabling this kind of treatment in such a significant
group of patients (37%, 92/248), including 37% (41/111) of
those with multiple sites involvement.
Our results encourage a focused, active treatment of
metastases if clinically feasible, even when multiple sites
involvement is present. Indeed, it has been long known
that surgical resection of liver metastasis in mCRC can
achieve long-term survival or cure in a high rate of pa-
tients (even > 50%), especially in oligometastatic patients
with liver involvement only, but the present results sup-
port that a long-term benefit can be achieved also in case
of metastatic spread to multiple sites [31, 32]. This obser-
vation is consistent with the recent trial results in patients
with unresectable metastases which demonstrated a sig-
nificantly longer OS thanks to a combined approach (sys-
temic treatment plus aggressive local treatment by
radiofrequency ablation ± resection) compared with sys-
temic therapy alone [33]. Conversely, randomized trials
comparing surgical and non-surgical approaches are lack-
ing. In our cohort, both approaches were associated with
an improved survival, but no conclusions can be inferred
regarding the superiority of a specific option since many
patients received both the treatments.
Bevacizumab at first line was the second variable which
resulted associated with long-term survival and first line
PFS despite a non-significant finding in terms of OS. This
benefit is consistent with literature data, and the missing
association with OS could be due to the limited sample
size of this group of patients [34]. These results highlight
Table 7 Multivariate binary logistic regression analysis of characteristics associated with long-term survival
Long-term survival
Variable OR 95% CI p
Age at metastasis ≤ 65 years (yes versus no) 1.95 0.96–3.97 0.064
Single site metastases versus multiple sites 1.76 0.87–3.58 0.114
First-line therapy Chemotherapy plus bevacizumab versus other 2.49 1.13–5.52 0.024
Surgical resection of metastasis (yes versus no) 3.96 1.96–8.02 < 0.001
Local non-surgical treatment of metastasis (yes versus no) 3.32 1.64–6.71 0.001
Table 8 Metastatic sites according to survival status and local treatment of metastases
Survivors < 4 years (n = 188) Long-term survivors (≥ 4 years) (n = 60)
Number of
metastatic sites
Local treatments for
metastases (n = 50)
No local treatments (n
= 138)
Total Local treatments for
metastases (n = 42)
No local treatments
(n = 18)
Total
Single site 21 76 97 30 10 40
Multiple sites 29 62 91 12 8 20
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the importance of long-term outcome analysis to compre-
hensively assess the efficacy of different prognostic factors
and treatments, both in terms of their combinations and
sequencing. The potential synergistic effect of a
bevacizumab-including regimen followed by metastasis
surgical resection should also be kept in mind considered
the recent data suggesting the positive impact of this ap-
proach on OS of mCRC [35, 36].
Nevertheless, these findings must be interpreted cau-
tiously due to the retrospective, real-life nature of the
study and its consequent, intrinsic limitations. During
the study period, some variations occurred both in terms
of the routine treatment protocols and the available clin-
ical trials. The limited sample size, in particular of the
long-survivors group, is a second limitation. Although
this drawback could have been tackled by broadening
the time period selected to collect the cases, it would
have significantly increased the heterogeneity in terms of
molecular assessment, treatments, and patients’ manage-
ment; thus, we tried to reach a compromise between
numerosity and heterogeneity to enable a meaningful
longitudinal analysis. Nevertheless, the characteristics of
such a real-life retrospective cohort allowed to identify
variables which were significantly associated with out-
come despite these changes over time [37]. Another
relevant perspective, which would have been interested
to investigate, is quality of life and patient-reported out-
comes measures which are especially relevant in long-
term cancer survivors [38]. This shortcoming could be
addressed by implementing a brief assessment of these
parameters into the routine clinical evaluation, but these
efforts are hindered by the ever-increasing demands on
healthcare staff.
Further studies, based on more recent cohorts, will
allow to verify the significance of the prognostic markers
here identified within specific mCRC molecular sub-
groups and their correlations with the newly introduced
drugs and regimens. As shown during the last few years
in melanoma or lung adenocarcinoma, new treatments
like immunotherapy and/or targeted therapies can dra-
matically reshape the therapeutic approaches, even in
patients with advanced/metastatic disease [39, 40]. This
is another promising perspective of tailored medicine
which shall not be undervalued: precision oncology
should not only rest on new molecularly driven drugs,
but also on the optimization of the already validated
treatments within the different clinical settings and for
each single patient.
Conclusions
Our study shows that long-term survival could often be
achieved in mCRC even in an era of limited molecular
characterization. Although the clinical setting of the
present study (a tertiary-level university hospital) has likely
played a role in achieving these overall results, local treat-
ment of metastases proved to be a clear predictor of long-
term survival. These data will also help compare and
interpret the long-term results of the new cohorts of pa-
tients which are now being treated according to more ex-
tensive molecular profiling and novel protocols.
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